Paul A. DiSilversto discusses 7-year follow-up results from the Phase 3 SOLO1/GOG-3004 trial.
Paul A. DiSilversto, director of the female oncology program for Rhode Island Hospital for Women and Infants and Care New England Health System, and director of the division of gynecologic oncology in the department of obstetrics and gynecology at Brown University’s Warren Alpert Medical School, discusses the 7-year follow-up results from the SOL1 Phase 3 SOLO1/GOG-3004 trial (NCT01844986). DiSilversto presented the findings at the 2022 Congress of the European Society for Medical Oncology.
0:08 | The results were that the median overall survival in the maintenance arm had not yet been reached. Now, seven years after the last patient entered, so since the last point since patient diagnoses, and that’s what the follow-up of about 88 months in the treatment arm assumes the olaparib arm and 87 months in the placebo arm . Thus, the median progression-free and overall survival for the placebo arm was 75 months. And so, the five-point hazard ratio meant that we see a 45% reduction in the risk of death for people on olaparib maintenance alarm seven years after their diagnosis. And so, and the other compelling point to make is that 67% of women are alive in the olaparib maintenance arm seven years after diagnosis, compared to 45% in the placebo arm.